A Model for Assessing the Cost-Effectiveness of Atorvastatin and Simvastatin in Achieving Canadian Low-Density Lipoprotein Cholesterol Targets

Clinical Therapeutics

Volumn 29, Issue 3, 2007, Pages 519-528

  Lachaine, Jean ^a   Merikle, Elizabeth ^b   Tarride, Jean Eric ^c   Montpetit, Martin ^b   Rinfret, Stéphane ^d  

^a UNIVERSITÉ DE MONTRÉAL   (Canada)

^b PFIZER INC   (United States)

^c MCMASTER UNIVERSITY   (Canada)

^d CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

health economics; hyperlipidemia; lipoproteins; risk factors

Indexed keywords

ATORVASTATIN; GENERIC DRUG; LOW DENSITY LIPOPROTEIN CHOLESTEROL; SIMVASTATIN;

ARTICLE; CANADA; CARDIOVASCULAR DISEASE; COST EFFECTIVENESS ANALYSIS; DRUG COST; DYSLIPIDEMIA; HUMAN; LIPOPROTEIN BLOOD LEVEL; REIMBURSEMENT; RISK FACTOR;

CANADA; CHOLESTEROL, LDL; COST-BENEFIT ANALYSIS; DRUG COSTS; DYSLIPIDEMIAS; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MODELS, ECONOMIC; PYRROLES; SIMVASTATIN;

EID: 34250210545     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/S0149-2918(07)80089-0     Document Type: Article

References (33)

1. The Growing Burden of Heart Disease and Stroke in Canada 2003 (2003), Heart and Stroke Foundation of Canada, Ottawa, Canada
2. Choi B.K., and Pak A.W. A method for comparing and combining cost-of-illness studies: An example from cardiovascular disease. Chronic Dis Can 23 (2002) 47-57
3. published correction appears in CMAJ. 2003;169:1149. Genest J., Frohlich J., Fodor G., McPherson R., and Working Group on Hypercholesterolemia and Other Dyslipidemias. Recommendations for the management of dyslipidemia and the prevention of cardiovascular disease: Summary of the 2003 update. CMAJ 169 (2003) 921-924
4. MacLean D.R., Petrasovits A., Nargundkar M., et al., Canadian Heart Health Surveys Research Group. Canadian Heart Health Surveys: A profile of cardiovascular risk. Survey methods and data analysis. CMAJ 146 (1992) 1969-1974
5. LaRosa J.C., He J., and Vupputuri S. Effect of statins on risk of coronary disease: A meta-analysis of randomized controlled trials. JAMA 282 (1999) 2340-2346
6. Law M.R., Wald N.J., and Rudnicka A.R. Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: Systematic review and metaanalysis. BMJ 326 (2003) 1423
7. Gould A.L., Rossouw J.E., Santanello N.C., et al. Cholesterol reduction yields clinical benefit: Impact of statin trials. Circulation 97 (1998) 946-952
8. Alzahrani T., Marrat S., and Haider A. Management of dyslipidemia in primary care. Cant Cardiol 19 (2003) 1499-1502
9. Andrews T.C., Ballantyne C.M., Hsia J.A., and Kramer J.H. Achieving and maintaining National Cholesterol Education Program low-density lipoprotein cholesterol goals with five statins. Am J Med 111 (2001) 185-191
10. McMurray J. The health economics of the treatment of hyperlipidemia and hypertension. Am J Hypertens 12 (1999) 99S-104S
11. Morrison A., and Glassberg H. Determinants of the cost-effectiveness of statins. J Manag Care Pharm 9 (2003) 544-551
12. Pickin D.M., McCabe C.J., Ramsay L.E., et al. Cost effectiveness of HMG-CoA reductase inhibitor (statin) treatment related to the risk of coronary heart disease and cost of drug treatment. Heart. 82 (1999) 325-332
13. Szucs T.D. Pharmaco-economic aspects of lipid-lowering therapy: Is it worth the price?. Eur Heart J. 19 Suppl M (1998) M22-M28
14. Perreault S., Levinton C., and Le Lorier J. Efficacy and cost of HMG-CoA reductase inhibitors in the treatment of patients with primary hyperlipidemia. Can J Clin Pharmacol 7 (2000) 144-154
15. Russell M.W., Huse D.M., Miller J.D., et al. Cost effectiveness of HMG-CoA reductase inhibition in Canada. Can J Clin Pharmacol 8 (2001) 9-16
16. IMS Health Canada. CompuScript, 12 months ending February 2005.
17. Wilson K., Marriott J., Fuller S., et al. A model to assess the cost effectiveness of statins in achieving the UK National Service Framework target cholesterol levels. Pharmaco Economics 21 Suppl 1 (2003) 1-11
18. Canadian Heart Health Database Centre. Available at: http://www.med. mun.ca/chhdbc/. Accessed February 23, 2005.
19. Available at:. e-Formulary. Accessed March 9. Ontario Drug Benefit Form ulary/Comparative Drug Index: Electronic Version (2005). http://www.health.gov.on.ca/english/providers/program/drugs/odbf_eformulary.html
20. Liste de Médicaments Assurés. 15th ed. (2005), La Régie de l'Assurance Maladie du Québec, Québec, Canada
21. PharmaCare Formulary (2005), British Columbia Ministry of Health Services, Victoria, Canada
22. Lachaine J., Rinfret S., Merikle E.P., and Tarride J.E. Persistence and adherence to cholesterol lowering agents: Evidence from Regie de l'Assurance Maladie du Quebec data. Am Heart J. 152 (2006) 164-169
23. published correction appears in Lancet. 2005;366:1358. Baigent C., Keech A., Kearney P.M., et al., Cholesterol Treatment Trialists' (CTT) Collaborators. Efficacy and safety of cholesterol-lowering treatment: Prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 366 (2005) 1267-1278
24. Cannon C.P., Steinberg B.A., Murphy S.A., et al. Meta-analysis of cardiovascular outcomes trials comparing inten sive versus moderate statin therapy. J Am Coll Cardiol 48 (2006) 438-445
25. published correction appears in PharmacoEconomics. 2006;24:106. Tarraga-Lopez P.J., Celada-Rodriguez A., Cerdan-Oliver M., et al. A pharmacoeconomic evaluation of statins in the treatment of hypercholesterolaemia in the primary care setting in Spain. PharmacoEconomics 23 (2005) 275-287
26. Plans-Rubio P. Cost-effectiveness analysis of cholesterol-lowering therapies in Spain. Am J Cardiovasc Drugs 6 (2006) 177-188
27. In: Repchinsky C., Welbanks L., Bisson R., et al. (Eds). CPS-Compendium of Pharmaceuticals and Specialties (2004), Canadian Pharmaceutical Association, Ottawa, Ontario
28. Koren M.J., Smith D.G., Hunninghake D.B., et al. The cost of reaching Na tional Cholesterol Education Program (NCEP) goals in hypercholesterolaemic patients. A comparison of atorvastatin, simvastatin, lovastatin and fluvastatin. PharmacoEconomics 14 (1998) 59-70
29. Hilleman D.E., Phillips J.O., Mohiuddin S.M., et al. A population-based treatto-target pharmacoeconomic analy sis of HMG-CoA reductase inhibitors in hypercholesterolemia. Clin Ther 21 (1999) 536-562
30. Huse D.M., Russell M.W., Miller J.D., et al. Cost-effectiveness of statins. Am J Cardiol. 82 (1998) 1357-1363
31. Smith D.G., and McBurney C.R. An economic analysis of the Atorvastatin Comparative Cholesterol Efficacy and Safety Study (ACCESS). PharmacoEconomics 21 Suppl 1 (2003) 13-23
32. Pearson T.A., Laurora I., Chu H., and Kafonek S. The lipid treatment assessment project (L-TAP): A multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals. Arch Intern Med 160 (2000) 459-467
33. EUROASPIRE I and II Group (European Action on Secondary Prevention by Intervention to Reduce Events). Clinical reality of coronary prevention guidelines: A comparison of EUROASPIRE I and II in nine countries. Lancet 357 (2001) 995-1001